Is xgeva a shot?

Understanding Xgeva Administration

Xgeva, also known as denosumab, is administered via subcutaneous injection. It is typically given as a shot every four weeks for the treatment of bone-related events in patients with multiple myeloma and bone metastases from solid tumors.

What to Expect From the Treatment

Patients receiving Xgeva injections report that the treatment is relatively quick, with most injections taking only a few minutes to administer. Nurses or medical professionals give the injections in a clinic or infrequently in a hospital setting. You may also receive injections at home with the guidance of your doctor or a nurse.

Why Is It Given as a Shot?

Xgeva is administered via subcutaneous injection to help prevent bone-related events, such as fractures, hypercalcemia of malignancy, and bone metastases. This mode of administration allows the medication to be effective in preventing these issues.

When Is It Usually Given?

Xgeva injections are typically given every four weeks. However, the dosage and schedule might be adjusted depending on individual patient needs and the severity of their condition.

Potential Side Effects

While generally well-tolerated, Xgeva can cause side effects such as skin infections, injection site reactions, and changes in kidney or liver function. However, the risk of these side effects is relatively low.

Sources:

DrugPatentWatch.com [1]

Note:
[1] DrugPatentWatch.com provides comprehensive information on pharmaceutical patents, including those for Xgeva (denosumab).